Needle-free Injection Systems Market Like to Cross $23,116 Million by 2023

Needle-free Injection Systems Market was valued at $8,166 million in 2016, and is projected to reach $23,116 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. The liquid-based needle free injection systems segment held more than two-thirds share of the total market in 2016.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2129

Needle-free injection systems are used to administer drugs and vaccines into patients without penetrating the skin. Improved immunization coverage, increase in demand for self-injection devices, increasing prevalence of chronic diseases such as diabetes and cancer, risk of exposure to communicable diseases due to needle stick injuries, and decrease in healthcare costs are expected to drive the market growth. However, lack of trained personnel and limited usage of needle-free injection systems for intravenous administration may restrict the market growth.

Subcutaneous injectors segment is expected to dominate the market throughout the analysis period. However, the intradermal injectors segment is expected to register the highest CAGR of 15.6%.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2129

Key Findings of the Needle-free Injection Systems Market:
o The spring injector systems segment is projected to grow at a CAGR of 15.6% during the forecast period.
o Disposable accounted for more than one-third share of the global needle-free injection systems market in 2016.
o In terms of product, the prefilled injector system segment is expected to register the highest CAGR of 17.7%.
o The use of needle-free injectors for vaccine delivery is expected to grow at the CAGR of 15.9%.
o France and Germany collectively contributed for more than one-third share of the European needle-free injection systems market in 2016.
o Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific needle-free injection systems market.

Asia-Pacific is projected to register the highest CAGR of 16.6%, owing to rise in incidence of chronic disease such as diabetes and hepatitis. In addition, surge in awareness of benefits of needle-free injection systems, such as elimination of needle phobia, offers a lucrative opportunity for the market growth.

The major companies profiled in the report are Antares Pharma, Inc., PharmaJet, Medical International Technology, Inc., INJEX Pharma AG, PenJet Corporation, Crossject needle-free injection systems, National Medical Products Inc., Valeritas, Inc., and European Pharma Group.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

This release was published on openPR.